More Meeting Highlights From ASH 2010

VBCM - Meeting Highlights - ASH 2010

FEATURED

Maintenance Therapy with Lenalidomide Doubled Remission Time

Young patients with multiple myeloma (MM) often receive high-dose therapy with autologous stem-cell transplantation (ASCT). Residual disease in evitably leads to relapse, and a research aim has been to determine ways to prevent this. In 2 phase 3 studies, maintenance therapy with lenalidomide resulted in a doubling of the time to disease progression. Read more.


MORE HIGHLIGHTS FROM ASH 2010

 

Related Items
Hematology Drug Pipeline Is Robust
VBCM - Meeting Highlights published on December 7, 2011 in ASH 2010
Bortezomib-Based Induction and Consolidation Emerging as a New Standard for Multiple Myeloma
VBCM - Meeting Highlights published on December 7, 2011 in ASH 2010
Advances in Multiple Myeloma Likely to Expand with Current Drugs in Development
VBCM - Meeting Highlights published on December 7, 2011 in ASH 2010
Cost-Effectiveness Analysis: Zoledronic Acid versus Clodronate
VBCM - Meeting Highlights published on December 7, 2011 in ASH 2010
Maintenance Therapy with Lenalidomide Doubled Remission Time
VBCM - Meeting Highlights published on December 7, 2011 in ASH 2010
Last modified: May 20, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology